{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:41:19Z","timestamp":1787503279544,"version":"build-2736575974"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["ST46"],"award-info":[{"award-number":["ST46"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01693-2","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:40:01Z","timestamp":1772815201000},"page":"1847-1868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous Skin Toxicities of Oncological Targeted Therapies: Comprehensive Overview of Mechanisms, Management, and Research Gaps\u2014A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Piotr","family":"Janicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Makowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jakubczyk-S\u0142abicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Bara\u0144ska-Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Owczarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6842-6123","authenticated-orcid":false,"given":"Magdalena","family":"G\u00f3rska-Ponikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"1693_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117677","volume":"292","author":"C Gao","year":"2025","unstructured":"Gao C, Wang W, Liu T, Li X, Yu Y, Wu J. Annual review of EGFR inhibitors in 2024. Eur J Med Chem. 2025;292:117677. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117677.","journal-title":"Eur J Med Chem"},{"issue":"12","key":"1693_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123126","volume":"15","author":"K-M Plachouri","year":"2023","unstructured":"Plachouri K-M, Florou V, Georgiou V, Georgiou S. Cutaneous side effects of modern targeted therapy and immunotherapy in patients with dermatological malignancies. Cancers. 2023;15(12):3126.","journal-title":"Cancers"},{"key":"1693_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.humpath.2023.04.014","volume":"140","author":"D Haynes","year":"2023","unstructured":"Haynes D, Morgan EE, Chu EY. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings. Hum Pathol. 2023;140:129\u201343. https:\/\/doi.org\/10.1016\/j.humpath.2023.04.014.","journal-title":"Hum Pathol"},{"issue":"16_suppl","key":"1693_CR4","doi-asserted-by":"publisher","first-page":"8641","DOI":"10.1200\/JCO.2025.43.16_suppl.8641","volume":"43","author":"JL Feldman","year":"2025","unstructured":"Feldman JL, Cho BC, Li W, et al. Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: results from the phase\u00a02 COCOON trial. J Clin Oncol. 2025;43(16_suppl):8641\u20138641. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8641.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1693_CR5","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1111\/jocd.15704","volume":"22","author":"C Yuan","year":"2023","unstructured":"Yuan C, Wang B. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review. J Cosmet Dermatol. 2023;22(8):2150\u20137. https:\/\/doi.org\/10.1111\/jocd.15704.","journal-title":"J Cosmet Dermatol"},{"key":"1693_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1283807","author":"H Dan","year":"2024","unstructured":"Dan H, Jiang Q, Jia X, Qi G, Zong D, Li Z. Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2023.1283807.","journal-title":"Front Med"},{"issue":"5","key":"1693_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","volume":"69","author":"CJ Ensslin","year":"2013","unstructured":"Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2013.06.038.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1693_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","volume":"78","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012;78(1):8\u201315. https:\/\/doi.org\/10.1016\/j.lungcan.2012.06.009.","journal-title":"Lung Cancer"},{"issue":"6","key":"1693_CR9","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"KJ Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144(6):1169\u201376. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04226.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1693_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-228968","volume":"12","author":"LV Matos","year":"2019","unstructured":"Matos LV, Pissarra A, Malheiro M, Pl\u00e1cido AN. Trichomegaly of the eyelashes induced by the epidermal growth factor receptor inhibitor cetuximab in the treatment of metastatic colorectal cancer. BMJ Case Rep. 2019;12(4):e228968. https:\/\/doi.org\/10.1136\/bcr-2018-228968.","journal-title":"BMJ Case Rep"},{"issue":"5","key":"1693_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4103\/idoj.IDOJ_133_18","volume":"9","author":"U Wollina","year":"2018","unstructured":"Wollina U. Systemic drug-induced chronic paronychia and periungual pyogenic granuloma. Indian Dermatol Online J. 2018;9(5):293. https:\/\/doi.org\/10.4103\/idoj.IDOJ_133_18.","journal-title":"Indian Dermatol Online J"},{"key":"1693_CR12","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.40555","volume":"104","author":"JS Lee","year":"2024","unstructured":"Lee JS, Woo J, Kim TM, Kim N, Keam B, Jo SJ. Skin toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitors and their influence on treatment adjustments in lung cancer patients. Acta Derm Venereol. 2024;104:adv40555. https:\/\/doi.org\/10.2340\/actadv.v104.40555.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1693_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jaad.2025.02.007","volume":"92","author":"I Arana","year":"2025","unstructured":"Arana I, Riew GJ, Rock A, Nambudiri VE, Modi B, Shi CR. Cutaneous toxicities associated with epidermal growth factor receptor and mesenchymal epithelial transition factor dual blockade via bispecific antibody amivantamab. J Am Acad Dermatol. 2025;92(6):1404\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2025.02.007.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1693_CR14","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1111\/jdv.20569","volume":"39","author":"M Starace","year":"2025","unstructured":"Starace M, Rapparini L, Cedirian S, et al. Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of 'Dermatology for Cancer Patients'. J Eur Acad Dermatol Venereol. 2025;39(9):e745-e749. https:\/\/doi.org\/10.1111\/jdv.20569","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1693_CR15","doi-asserted-by":"publisher","first-page":"1457226","DOI":"10.3389\/fphar.2024.1457226","volume":"15","author":"J Qian","year":"2024","unstructured":"Qian J, Wan J, Yao Q, et al. \u00a0Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1457226.\u00a0https:\/\/doi.org\/10.3389\/fphar.2024.1457226.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1693_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010141","volume":"15","author":"M Garutti","year":"2022","unstructured":"Garutti M, Bergnach M, Polesel J, Palmero L, Pizzichetta MA, Puglisi F. BRAF and MEK inhibitors and their toxicities: a meta-analysis. Cancers (Basel). 2022;15(1):141. https:\/\/doi.org\/10.3390\/cancers15010141.","journal-title":"Cancers (Basel)"},{"issue":"47","key":"1693_CR17","doi-asserted-by":"publisher","first-page":"83280","DOI":"10.18632\/oncotarget.21059","volume":"8","author":"L Peng","year":"2017","unstructured":"Peng L, Wang Y, Hong Y, et al. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF\/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 2017;8(47):83280\u201391. https:\/\/doi.org\/10.18632\/oncotarget.21059.","journal-title":"Oncotarget"},{"issue":"S1","key":"1693_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(S1):31\u20139. https:\/\/doi.org\/10.1007\/s40257-018-0384-3.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1693_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer. 2021;7(1):56. https:\/\/doi.org\/10.1038\/s41523-021-00265-1.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1693_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.bjc.6602875","volume":"94","author":"I Laux","year":"2006","unstructured":"Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer. 2006;94(1):85\u201392. https:\/\/doi.org\/10.1038\/sj.bjc.6602875.","journal-title":"Br J Cancer"},{"issue":"3","key":"1693_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","volume":"114","author":"ME Lacouture","year":"2009","unstructured":"Lacouture ME, Laabs SM, Koehler M, et al.\u00a0Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009;114(3):485\u201393. https:\/\/doi.org\/10.1007\/s10549-008-0020-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"1693_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/jjco\/hyt110","volume":"43","author":"K Nakano","year":"2013","unstructured":"Nakano K, Komatsu K, Kubo T, et al. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol. 2013;43(10):1023\u20139. https:\/\/doi.org\/10.1093\/jjco\/hyt110.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"1693_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","volume":"1","author":"E Nagore","year":"2000","unstructured":"Nagore E, Insa A, Sanmartn O. Antineoplastic therapy induced palmar plantar erythrodysesthesia (hand\u2013foot) syndrome. Am J Clin Dermatol. 2000;1(4):225\u201334. https:\/\/doi.org\/10.2165\/00128071-200001040-00004.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1693_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11523-015-0409-2","volume":"11","author":"SC Sodergren","year":"2016","unstructured":"Sodergren SC, Copson E, White A, et al. Systematic review of the side effects associated with anti-HER2-targeted therapies used in the treatment of breast cancer, on behalf of the EORTC quality of life group. Target Oncol. 2016;11(3):277\u201392. https:\/\/doi.org\/10.1007\/s11523-015-0409-2.","journal-title":"Target Oncol"},{"issue":"2","key":"1693_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","volume":"23","author":"E Raschi","year":"2022","unstructured":"Raschi E, Fusaroli M, La Placa M, et al. \u00a0Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol. 2022;23(2):247\u201355. https:\/\/doi.org\/10.1007\/s40257-021-00645-0.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1693_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-021-06169-9","volume":"188","author":"S Chawla","year":"2021","unstructured":"Chawla S, Hill A, Fearfield L, Johnston S, Parton M, Heelan K. Cutaneous toxicities occurring during palbociclib (CDK4\/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience. Breast Cancer Res Treat. 2021;188(2):535\u201345. https:\/\/doi.org\/10.1007\/s10549-021-06169-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"1693_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143658","volume":"15","author":"P Sollena","year":"2023","unstructured":"Sollena P, Vasiliki N, Kotteas E, et al. \u00a0Cyclin-dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV task force \u2018dermatology for cancer patients\u2019 international study. Cancers. 2023;15(14):3658. https:\/\/doi.org\/10.3390\/cancers15143658.","journal-title":"Cancers"},{"issue":"3","key":"1693_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annder.2022.11.013","volume":"150","author":"V Sibaud","year":"2023","unstructured":"Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice. Ann Dermatol Venereol. 2023;150(3):208\u201312. https:\/\/doi.org\/10.1016\/j.annder.2022.11.013.","journal-title":"Ann Dermatol Venereol"},{"issue":"7","key":"1693_CR29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","volume":"44","author":"M Silvestri","year":"2021","unstructured":"Silvestri M, Cristaudo A, Morrone A, et al. \u00a0Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review. Drug Saf. 2021;44(7):725\u201332. https:\/\/doi.org\/10.1007\/s40264-021-01071-1.","journal-title":"Drug Saf"},{"issue":"25","key":"1693_CR30","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1693_CR31","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"key":"1693_CR32","doi-asserted-by":"publisher","DOI":"10.7241\/ourd.20232.13","author":"P Preetham","year":"2023","unstructured":"Preetham P, Sudha S, Kabilan N. Dermatoses induced by multikinase inhibitors: a case report. Our Dermatol Online. 2023. https:\/\/doi.org\/10.7241\/ourd.20232.13.","journal-title":"Our Dermatol Online"},{"issue":"6","key":"1693_CR33","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s00520-014-2520-9","volume":"23","author":"PR Massey","year":"2015","unstructured":"Massey PR, Okman JS, Wilkerson J, Cowen EW. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer. 2015;23(6):1827\u201335. https:\/\/doi.org\/10.1007\/s00520-014-2520-9.","journal-title":"Support Care Cancer"},{"issue":"10","key":"1693_CR34","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1101\/gad.1653708","volume":"22","author":"J Andrae","year":"2008","unstructured":"Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276\u2013312. https:\/\/doi.org\/10.1101\/gad.1653708.","journal-title":"Genes Dev"},{"issue":"2","key":"1693_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1600-0609.2004.00351.x","volume":"74","author":"M Breccia","year":"2005","unstructured":"Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol. 2005;74(2):121\u20133. https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00351.x.","journal-title":"Eur J Haematol"},{"issue":"1","key":"1693_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2340\/00015555-0758","volume":"90","author":"N Kuraishi","year":"2010","unstructured":"Kuraishi N, Nagai Y, Hasegawa M, Ishikawa O. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. Acta Derm Venereol. 2010;90(1):73\u20136. https:\/\/doi.org\/10.2340\/00015555-0758.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1693_CR37","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/bjd.15738","volume":"177","author":"C Dessinioti","year":"2017","unstructured":"Dessinioti C, Antoniou C, Stratigos AJ. From basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dots. Br J Dermatol. 2017;177(6):1485\u201394. https:\/\/doi.org\/10.1111\/bjd.15738.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1693_CR38","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40257-024-00870-3","volume":"25","author":"AS Farberg","year":"2024","unstructured":"Farberg AS, Portela D, Sharma D, Kheterpal M. Evaluation of the tolerability of hedgehog pathway inhibitors in the treatment of advanced basal cell carcinoma: a narrative review of treatment strategies. Am J Clin Dermatol. 2024;25(5):779\u201394. https:\/\/doi.org\/10.1007\/s40257-024-00870-3.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1693_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40257-023-00763-x","volume":"24","author":"A Nguyen","year":"2023","unstructured":"Nguyen A, Xie P, Litvinov IV, Lefran\u00e7ois P. Efficacy and safety of sonic hedgehog inhibitors in basal cell carcinomas: an updated systematic review and meta-analysis (2009\u20132022). Am J Clin Dermatol. 2023;24(3):359\u201374. https:\/\/doi.org\/10.1007\/s40257-023-00763-x.","journal-title":"Am J Clin Dermatol"},{"issue":"16_suppl","key":"1693_CR40","doi-asserted-by":"publisher","first-page":"9583","DOI":"10.1200\/JCO.2025.43.16_suppl.9583","volume":"43","author":"F Herms","year":"2025","unstructured":"Herms F, Djermane M, Beylot-Barry M, et al. Comparison of the tolerability and safety of hedgehog inhibitors in real-life: a cohort of 330 patients with locally advanced basal cell carcinoma. J Clin Oncol. 2025;43(16_suppl):9583\u20139583. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.9583.","journal-title":"J Clin Oncol"},{"key":"1693_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251324889","author":"S Kang","year":"2025","unstructured":"Kang S, Kim S-B. Toxicities and management strategies of emerging antibody\u2013drug conjugates in breast cancer. Ther Adv Med Oncol. 2025. https:\/\/doi.org\/10.1177\/17588359251324889.","journal-title":"Ther Adv Med Oncol"},{"issue":"20","key":"1693_CR42","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","volume":"12","author":"BM Tijink","year":"2006","unstructured":"Tijink BM, Buter J, de Bree R, et al. A phase\u00a0I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12(20):6064\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0910.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1693_CR43","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","volume":"44","author":"H Riechelmann","year":"2008","unstructured":"Riechelmann H, Sauter A, Golze W, et al. Phase\u00a0I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008;44(9):823\u20139. https:\/\/doi.org\/10.1016\/j.oraloncology.2007.10.009.","journal-title":"Oral Oncol"},{"key":"1693_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102113","volume":"62","author":"A D\u2019Arienzo","year":"2023","unstructured":"D\u2019Arienzo A, Verrazzo A, Pagliuca M, et al. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine. 2023;62:102113. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102113.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"1693_CR45","doi-asserted-by":"publisher","first-page":"595.e1","DOI":"10.1016\/j.urolonc.2025.05.016","volume":"43","author":"G Gazzoni","year":"2025","unstructured":"Gazzoni G, Michelon I, Vilbert M, et al. Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: a systematic review and meta-analysis. Urol Oncol Semin Orig Investig. 2025;43(10):595.e1-595.e11. https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.016.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"29","key":"1693_CR46","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592\u2013600. https:\/\/doi.org\/10.1200\/JCO.19.01140.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1693_CR47","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1200\/JCO.2021.39.15_suppl.3049","volume":"39","author":"Y Oh","year":"2021","unstructured":"Oh Y, Bang A, Kurtansky N, Khan N, Pulitzer M, Noor S. Dermatologic adverse events of brentuximab vedotin: characteristics, management, and their relationship with dose regimen. J Clin Oncol. 2021;39(15_suppl):3049\u20133049. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.3049.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1693_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1814213.","journal-title":"N Engl J Med"},{"issue":"16","key":"1693_CR49","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"1693_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231200454","author":"M Reinisch","year":"2023","unstructured":"Reinisch M, Bruzas S, Spoenlein J, et al. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther Adv Med Oncol. 2023. https:\/\/doi.org\/10.1177\/17588359231200454.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"1693_CR51","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1002\/onco.13552","volume":"26","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Anadkat MJ, et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist. 2021;26(2):e316\u201326. https:\/\/doi.org\/10.1002\/onco.13552.","journal-title":"Oncologist"},{"key":"1693_CR52","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00896","author":"R Grochot","year":"2025","unstructured":"Grochot R, Joshi K, Cammarota A, et al. Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies: a pooled analysis of early-phase clinical trials. JCO Precis Oncol. 2025. https:\/\/doi.org\/10.1200\/PO-24-00896.","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"1693_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204","volume":"4","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Verstovsek S. Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med. 2023;4(10):101204. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101204.","journal-title":"Cell Rep Med"},{"issue":"16","key":"1693_CR54","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","volume":"10","author":"T Ishida","year":"2004","unstructured":"Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor\u00a03 and CC chemokine receptor\u00a04 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10(16):5494\u2013500. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0371.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1693_CR55","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","volume":"119","author":"K Ferenczi","year":"2002","unstructured":"Ferenczi K, Fuhlbrigge RC, Kupper TS, Pinkus JL, Pinkus GS. Increased CCR4 expression in cutaneous T\u00a0cell lymphoma. J Invest Dermatol. 2002;119(6):1405\u201310. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.19610.x.","journal-title":"J Invest Dermatol"},{"issue":"21","key":"1693_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215542","volume":"13","author":"O Yoshie","year":"2021","unstructured":"Yoshie O. CCR4 as a therapeutic target for cancer immunotherapy. Cancers. 2021;13(21):5542. https:\/\/doi.org\/10.3390\/cancers13215542.","journal-title":"Cancers"},{"issue":"10","key":"1693_CR57","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1182\/bloodadvances.2020001641","volume":"4","author":"M Saito","year":"2020","unstructured":"Saito M, Ishii T, Urakawa I, et al. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma. Blood Adv. 2020;4(10):2180\u201391. https:\/\/doi.org\/10.1182\/bloodadvances.2020001641.","journal-title":"Blood Adv"},{"issue":"11","key":"1693_CR58","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, et al. Multicenter phase\u00a0II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor\u00a04 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363. https:\/\/doi.org\/10.1200\/JCO.2013.52.0924.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1693_CR59","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase\u00a0II study. J Clin Oncol. 2012;30(8):837\u201342. https:\/\/doi.org\/10.1200\/JCO.2011.37.3472.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1693_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1684\/ejd.2021.4002","volume":"31","author":"AS Algarni","year":"2021","unstructured":"Algarni AS, Ram-Wolff C, Bagot M, De Masson A. Mogamulizumab-induced vitiligo in patients with S\u00e9zary syndrome: three cases. Eur J Dermatol. 2021;31(2):213\u20136. https:\/\/doi.org\/10.1684\/ejd.2021.4002.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"1693_CR61","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","volume":"157","author":"KE Hirotsu","year":"2021","unstructured":"Hirotsu KE, Neal TM, Khodadoust MS, et al. Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or S\u00e9zary syndrome. JAMA Dermatol. 2021;157(6):700. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0877.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1693_CR62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/1346-8138.12419","volume":"41","author":"K Yonekura","year":"2014","unstructured":"Yonekura K, Kanzaki T, Gunshin K, et al. Effect of anti-CCR 4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia\u2013lymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol. 2014;41(3):239\u201344. https:\/\/doi.org\/10.1111\/1346-8138.12419.","journal-title":"J Dermatol"},{"issue":"6","key":"1693_CR63","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaad.2024.08.037","volume":"91","author":"D Tomsitz","year":"2024","unstructured":"Tomsitz D, Kerl K, French LE, Heinzerling L. Clinical and pathological characterization of tebentafusp-associated skin toxicity: a cohort study with 33 patients. J Am Acad Dermatol. 2024;91(6):1136\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2024.08.037.","journal-title":"J Am Acad Dermatol"},{"issue":"22","key":"1693_CR64","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton MR, McAlpine C, Woodcock VK, et al. Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26(22):5869\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1247.","journal-title":"Clin Cancer Res"},{"key":"1693_CR65","doi-asserted-by":"publisher","DOI":"10.5070\/D329662993","author":"LM Fahmy","year":"2024","unstructured":"Fahmy LM, Schreidah CM, McDonnell DE, Carvajal RD, Magro CM, Geskin LJ. Cutaneous type\u00a0IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatol Online J. 2024. https:\/\/doi.org\/10.5070\/D329662993.","journal-title":"Dermatol Online J"},{"issue":"24","key":"1693_CR66","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"1693_CR67","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase\u00a02 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8036\u20138036. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8036.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1693_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9","volume":"14","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14(1):24. https:\/\/doi.org\/10.1038\/s41408-023-00966-9.","journal-title":"Blood Cancer J"},{"key":"1693_CR69","first-page":"90","volume":"155","author":"US Department of Health and Human Services","year":"2017","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) v5.0. Cancer Ther Eval Progr. 2017;155:90\u20132.","journal-title":"Cancer Ther Eval Progr"},{"issue":"3","key":"1693_CR70","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/jdv.17855","volume":"36","author":"Z Apalla","year":"2022","unstructured":"Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u2018Dermatology for cancer patients\u2019 position statement. J Eur Acad Dermatol Venereol. 2022;36(3):332\u201350. https:\/\/doi.org\/10.1111\/jdv.17855.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1693_CR71","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000277656","volume":"33","author":"JC Hassel","year":"2010","unstructured":"Hassel JC, Kripp M, Al-Batran S, Hofheinz R-D. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie. 2010;33(3):94\u20138. https:\/\/doi.org\/10.1159\/000277656.","journal-title":"Onkologie"},{"issue":"6","key":"1693_CR72","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","volume":"32","author":"DM Barrios","year":"2021","unstructured":"Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol. 2021;32(6):736\u201345. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.016.","journal-title":"Ann Oncol"},{"issue":"6","key":"1693_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007324","volume":"11","author":"AM-S Kuo","year":"2023","unstructured":"Kuo AMS, Gu S, Stoll J, et al. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. 2023;11(6):e007324. https:\/\/doi.org\/10.1136\/jitc-2023-007324.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1693_CR74","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255\u201368. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132.","journal-title":"J Am Acad Dermatol"},{"key":"1693_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70149","author":"D Fattore","year":"2025","unstructured":"Fattore D, Apalla Z, Freites-Martinez A, et al. Prevention and management of cutaneous immune-related adverse events: EADV Task Force statement. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.70149.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1693_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123126","volume":"15","author":"K-M Plachouri","year":"2023","unstructured":"Plachouri K-M, Florou V, Georgiou V, Georgiou S. Cutaneous side effects of modern targeted therapy and immunotherapy in patients with dermatological malignancies. Cancers (Basel). 2023;15(12):3126.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1693_CR77","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1159\/000513233","volume":"237","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Geat D, Mattiucci A, Lombardo F, Santo A, Girolomoni G. Incidence of adverse cutaneous reactions to epidermal growth factor receptor inhibitors in patients with non-small-cell lung cancer. Dermatology. 2021;237(6):929\u201333. https:\/\/doi.org\/10.1159\/000513233.","journal-title":"Dermatology"},{"issue":"4","key":"1693_CR78","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/jdv.20391","volume":"39","author":"Z Apalla","year":"2025","unstructured":"Apalla Z, Freites-Martinez A, Grafanaki K, et al. Management of human epidermal growth factor receptor inhibitors-related acneiform rash: a position paper based on the first Europe\/ USA Delphi consensus process. J Eur Acad Dermatol Venereol. 2025;39(4):730\u201341. https:\/\/doi.org\/10.1111\/jdv.20391.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1693_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18340","author":"JH Lee","year":"2019","unstructured":"Lee JH, Ju HJ, Kwon HS, et al. Efficacy of topical epidermal growth factor cream for patients with epidermal growth factor receptor inhibitor-induced acneiform eruption: a randomized controlled trial. Br Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18340.","journal-title":"Br Dermatol"},{"issue":"3","key":"1693_CR80","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10549-023-07217-2","volume":"204","author":"AS Bang","year":"2024","unstructured":"Bang AS, Fay CJ, LeBoeuf NR, et al. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Res Treat. 2024;204(3):643\u20137. https:\/\/doi.org\/10.1007\/s10549-023-07217-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"1693_CR81","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152(10):1128. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2226.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1693_CR82","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","volume":"33","author":"Z Ren","year":"2015","unstructured":"Ren Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand\u2013foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(8):894\u2013900. https:\/\/doi.org\/10.1200\/JCO.2013.52.9651.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1693_CR83","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","volume":"17","author":"K Chanprapaph","year":"2016","unstructured":"Chanprapaph K, Rutnin S, Vachiramon V. Multikinase inhibitor-induced hand\u2013foot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol. 2016;17(4):387\u2013402. https:\/\/doi.org\/10.1007\/s40257-016-0197-1.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1693_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08160-0","volume":"31","author":"A Minta","year":"2023","unstructured":"Minta A, Rose L, Park C, et al. Retrospective cohort study of CDK4\/6-inhibitor-induced alopecia in breast cancer patients. Support Care Cancer. 2023;31(12):717. https:\/\/doi.org\/10.1007\/s00520-023-08160-0.","journal-title":"Support Care Cancer"},{"key":"1693_CR85","doi-asserted-by":"publisher","DOI":"10.5070\/D3272052385","author":"G Nazzaro","year":"2021","unstructured":"Nazzaro G, Giacalone S, Bortoluzzi P, Veraldi S, Marzano AV. Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature. Dermatol Online J. 2021. https:\/\/doi.org\/10.5070\/D3272052385.","journal-title":"Dermatol Online J"},{"key":"1693_CR86","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/CCID.S223317","volume":"12","author":"M Starace","year":"2019","unstructured":"Starace M, Alessandrini A, Baraldi C, Piraccini BM. Erosive pustular dermatosis of the scalp: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:691\u20138. https:\/\/doi.org\/10.2147\/CCID.S223317.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"1693_CR87","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bjd.19026","volume":"184","author":"MH Junejo","year":"2021","unstructured":"Junejo MH, Kentley J, Rajpopat M, Tan XL, Mohd Mustapa MF, Harwood CA. Therapeutic options for erosive pustular dermatosis of the scalp: a systematic review. Br J Dermatol. 2021;184(1):25\u201333. https:\/\/doi.org\/10.1111\/bjd.19026.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1693_CR88","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","volume":"128","author":"C-W Wang","year":"2018","unstructured":"Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985\u201396. https:\/\/doi.org\/10.1172\/JCI93349.","journal-title":"J Clin Invest"},{"key":"1693_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1454015","author":"M Zhang","year":"2024","unstructured":"Zhang M, Fu Y, Song Y, Gao X, Wang J, Zhang B. Immune-related toxic epidermal necrolysis affecting trachea mucosal epithelium: a case report and literature review. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1454015.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1693_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics7020034","volume":"7","author":"T Ciardiello","year":"2020","unstructured":"Ciardiello T, Pinto D, Marotta L, Giuliani G, Rinaldi F. Effects of fermented oils on alpha-biodiversity and relative abundance of cheek resident skin microbiota. Cosmetics. 2020;7(2):34. https:\/\/doi.org\/10.3390\/cosmetics7020034.","journal-title":"Cosmetics"},{"issue":"1","key":"1693_CR91","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cpt.698","volume":"102","author":"M Egert","year":"2017","unstructured":"Egert M, Simmering R, Riedel C. The association of the skin microbiota with health, immunity, and disease. Clin Pharmacol Ther. 2017;102(1):62\u20139. https:\/\/doi.org\/10.1002\/cpt.698.","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"1693_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27154845","volume":"27","author":"W Majchrzak","year":"2022","unstructured":"Majchrzak W, Motyl I, \u015amigielski K. Biological and cosmetical importance of fermented raw materials: an overview. Molecules. 2022;27(15):4845. https:\/\/doi.org\/10.3390\/molecules27154845.","journal-title":"Molecules"},{"issue":"4","key":"1693_CR93","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s13770-024-00695-5","volume":"22","author":"JH Kim","year":"2025","unstructured":"Kim JH, Kim J-E, Kang S-J, Yoon J-K. Exosomes and exosome-mimetics for atopic dermatitis therapy. Tissue Eng Regen Med. 2025;22(4):381\u201396. https:\/\/doi.org\/10.1007\/s13770-024-00695-5.","journal-title":"Tissue Eng Regen Med"},{"issue":"1","key":"1693_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02215-4","volume":"24","author":"J Li","year":"2025","unstructured":"Li J, Wang J, Chen Z. Emerging role of exosomes in cancer therapy: progress and challenges. Mol Cancer. 2025;24(1):13. https:\/\/doi.org\/10.1186\/s12943-024-02215-4.","journal-title":"Mol Cancer"},{"issue":"1","key":"1693_CR95","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12967-024-05744-0","volume":"23","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Yang H, Xue Z, Tang H, Chen X, Liao Y. Mesenchymal stem cells-derived small extracellular vesicles and apoptotic extracellular vesicles for wound healing and skin regeneration: a systematic review and meta-analysis of preclinical studies. J Transl Med. 2025;23(1):364. https:\/\/doi.org\/10.1186\/s12967-024-05744-0.","journal-title":"J Transl Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01693-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:27Z","timestamp":1775101107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01693-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01693-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Piotr Janicki, Anna Makowska, Anna Jakubczyk-S\u0142abicka, Renata Zaucha, Wioletta Bara\u0144ska-Rybak, Witold Owczarek and Magdalena G\u00f3rska-Ponikowska declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}